abstract |
The invention relates, inter alia, to antibodies that can bind to the interleukin-1 receptor accessory protein (IL1RAP). The antibodies of the invention comprise novel light chain and heavy chain sequences and bind to IL1RAP with high efficiency and specificity. The anti-IL1RAP antibodies of the invention are used, inter alia, for the treatment of cancers expressing IL1RAP, such as LMA. |